Skip to main content

Maryles Joel Michael's Form 4 filing

Chemomab Therapeutics Ltd. (CMMB) · filed Mar 21, 2022

Accession no.
0001178913-22-001181
Filed
Mar 21, 2022
Trade date
Apr 19, 2021-Mar 18, 2022
Filing delay
336 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market purchases total $4.34K. It was filed 336 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Maryles Joel MichaelCIK 0001850990Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 18, 2022American Depositary SharesPPurchaseAcquired+500$4.32+$2,160500Direct
Mar 18, 2022American Depositary SharesPPurchaseAcquired+500$4.36+$2,1801,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 7, 2022American Depositary SharesAGrant or awardAcquired+6,820$0.00$06,820DirectDuplicate filing
Apr 19, 2021American Depositary SharesAGrant or awardAcquired+11,884$0.00$011,884DirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)